The estimated Net Worth of Laurence M Corash is at least $6.2 Milion dollars as of 12 March 2024. Laurence Corash owns over 28,427 units of Cerus stock worth over $4,796,467 and over the last 21 years he sold CERS stock worth over $118,223. In addition, he makes $1,287,730 as Chief Scientific Officer at Cerus.
Sign up
Laurence Corash CERS stock SEC Form 4 insiders trading
Laurence has made over 50 trades of the Cerus stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 28,427 units of CERS stock worth $57,423 on 12 March 2024.
The largest trade he's ever made was exercising 162,750 units of Cerus stock on 3 October 2014 worth over $296,205. On average, Laurence trades about 22,661 units every 72 days since 2003. As of 12 March 2024 he still owns at least 2,339,740 units of Cerus stock.
You can see the complete history of Laurence Corash stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Laurence Corash biography
Dr. Laurence M. Corash M.D. serves as Chief Scientific Officer of the Company. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008, Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash also served on our Board of Directors from December 2002 to June 2019. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011, Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability.
What is the salary of Laurence Corash?
As the Chief Scientific Officer of Cerus, the total compensation of Laurence Corash at Cerus is $1,287,730. There are 2 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
How old is Laurence Corash?
Laurence Corash is 76, he's been the Chief Scientific Officer of Cerus since 2019. There are no older and 13 younger executives at Cerus.
What's Laurence Corash's mailing address?
Laurence's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash a Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Laurence Corash stock trades at Cerus
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director